American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 522-535 , March 2009

Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the Centers for Disease Control and Prevention

  • Andrew S. Levey, MD

      Affiliations

    • Division of Nephrology, Tufts Medical Center, Boston, MA
    • Corresponding Author InformationAddress correspondence to Andrew S. Levey, MD, Division of Nephrology, Tufts Medical Center, 800 Washington St, Box 391, Boston, MA 02111
    • ,
  • Anton C. Schoolwerth, MD, MSHA

      Affiliations

    • Dartmouth-Hitchcock Medical Center, Hanover, NH
    • ,
  • Nilka Ríos Burrows, MPH, MT

      Affiliations

    • Division of Diabetes Translation, Centers for Disease Control and Prevention
    • Centers for Disease Control and Prevention
    • ,
  • Desmond E. Williams, MD, PhD

      Affiliations

    • Centers for Disease Control and Prevention
    • ,
  • Karma Rabon Stith, PhD, CHES

      Affiliations

    • Danya Int, Inc
    • ,
  • William McClellan, MD, MPH

      Affiliations

    • Rollins School of Public Health, Emory University, Atlanta, GA

Received 8 September 2008 ,Accepted 24 November 2008.

References 

  1. Schoolwerth AC, Engelgau MM, Hostetter TH, et al. Chronic kidney disease: A public health problem that needs a public health action plan. Prev Chronic Dis. 2006;[serial online], Apr http://www.cdc.gov/pcd/issues/2006/apr/05_0105.htmAccessed December 21, 2008
  2. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1–S266
  3. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  4. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–2100
  5. Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: A position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50:169–180
  6. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA. 2003;289:2560–2572
  7. American Diabetes Association. Standards of medical care in diabetes—2006. Diabetes Care. 2006;29(suppl 1):S1–S71
  8. Parker TF, Blantz R, Hostetter T, et al. The chronic kidney disease initiative. J Am Soc Nephrol. 2004;15:708–716
  9. Hull AR, Parker TF. Proceedings from the Morbidity, Mortality and Prescription of Dialysis Symposium, Dallas, TX, September 15-17, 1989. Am J Kidney Dis. 1990;15:375–383
  10. Centers for Disease Control and Prevention. Chronic kidney disease initiative. http://www.cdc.gov/diabetes/projects/kidney.htmAccessed November 11, 2008
  11. US Renal Data System. USRDS 2007 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  12. Burrows NR, Wang J, Geiss LS, Venkat Narayan KM, Engelgau MM. Incidence of end-stage renal disease among persons with diabetes—United States 1990-2002. MMWR Morbid Mortal Wkly Rep. 2005;54:1097–1100
  13. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  14. Coresh J, Astor B, Greene T, Eknoyan G, Levey A. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12
  15. US Renal Data System. USRDS 2005 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005;
  16. Yach D, Hawkes C, Gould CL, Hofman KJ. The global burden of chronic diseases: Overcoming impediments to prevention and control. JAMA. 2004;291:2616–2622
  17. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. J Am Soc Nephrol. 2002;13(suppl 1):S37–S40
  18. Chen J, Wildman RP, Gu D, et al. Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years. Kidney Int. 2005;68:2837–2845
  19. Hallan SI, Coresh J, Astor BC, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006;17:2275–2284
  20. Chadban SJ, Briganti EM, Kerr PG, et al. Prevalence of kidney damage in Australian adults: The AusDiab Kidney Study. J Am Soc Nephrol. 2003;14(suppl 2):S131–S138
  21. Centers for Disease Control and Prevention. Disease Public Health Resource (Diabetes Project: Kidney Disease Initiative). http://www.cdc.gov/diabetes/projects/kidney.htm[updated January 11, 2008]. Accessed December 29, 2008
  22. Gordon RS. An operational classification of disease prevention. Public Health Rep. 1983;98:107–109
  23. Froom P, Benbassat J. Inconsistencies in the classification of preventive interventions. Prev Med. 2000;31:153–158
  24. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941–1951
  25. National Kidney Foundation. Kidney Early Evaluation Program (KEEP) annual data report 2006. Am J Kidney Dis. 2007;49(suppl 3):S1–S130
  26. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49(suppl 2):S1–S180
  27. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  28. Brosius FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: A science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: Developed in collaboration with the National Kidney Foundation. Circulation. 2006;114:1083–1087
  29. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):S79–S83
  30. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Nutrition in Chronic Renal Failure. Am J Kidney Dis. 2000;35(suppl 2):S1–S140
  31. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Management of Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis. 2003;41(suppl 3):S1–S92
  32. Kidney Disease: Improving Global Outcomes (KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease). Kidney Int Suppl. 2008;109:S1–S99
  33. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S1–S146
  34. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis. 2003;42(suppl 3):S1–S202
  35. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients (American Society of Transplantation). J Am Soc Nephrol. 2000;11(suppl 15):S1–S86
  36. Renal Physicians Association. Clinical Practice Guidelines on Shared Decision-Making in the Appropriate Initiation of and Withdrawal From Dialysis. Washington DC: Renal Physicians Association; 1997;
  37. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Vascular Access. Am J Kidney Dis. 2006;48(suppl 1):S176–S247
  38. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Hemodialysis Adequacy, Update 2006. Am J Kidney Dis. 2006;48(suppl 1):S2–S90
  39. National Kidney Foundation. KDOQI Clinical Practice Guidelines for Peritoneal Adequacy, Update 2006. Am J Kidney Dis. 2006;48(suppl 1):S91–S97
  40. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis. 2005;45(suppl 3):S1–S153
  41. Kasiske BL, Cangro CB, Hariharan S, et al. The evaluation of renal transplantation candidates: Clinical practice guidelines. Am J Transplant. 2001;1(suppl 2):S3–S95
  42. Bolton WK. Renal Physicians Association clinical practice guideline: Appropriate patient preparation for renal replacement therapy: Guideline number 3. J Am Soc Nephrol. 2003;14:1406–1410
  43. US Census Bureau. Annual estimates of the population by five-year age groups and for sex for the United States: April 1, 2000 to July 1, 2006. http://www.census.gov/popest/national/asrh/NC-EST2006/NC-EST2006=01.xlsAccessed December 3, 2008
  44. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics—2006 Update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85–e151
  45. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2005. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2005;
  46. O'Hare AM, Bertenthal D, Covinsky KE, et al. Mortality risk stratification in chronic kidney disease: One size for all ages?. J Am Soc Nephrol. 2006;17:846–853
  47. Kausz AT, Guo H, Pereira BJ, Collins AJ, Gilbertson DT. General medical care among patients with chronic kidney disease: Opportunities for improving outcomes. J Am Soc Nephrol. 2005;16:3092–3101
  48. Gilbertson DT, Liu J, Xue JL, et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol. 2005;16:3736–3741
  49. Li S, Foley RN, Collins AJ. Anemia and cardiovascular disease, hospitalization, end stage renal disease, and death in older patients with chronic kidney disease. Int Urol Nephrol. 2005;37:395–402
  50. Coresh J, Byrd-Holt D, Astor B, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180–188
  51. Centers for Disease Control and Prevention. Prevalence of chronic kidney disease and associated risk factors—United States, 1999-2004. MMWR Morbid Mortal Wkly Rep. 2007;56:161–165
  52. Sehgal AR. Impact of quality improvement efforts on race and sex disparities in hemodialysis. JAMA. 2003;289:996–1000
  53. McClellan WM, Hodgin E, Pastan S, McAdams L, Soucie M. A randomized evaluation of two health care quality improvement program (HCQIP) interventions to improve the adequacy of hemodialysis care of ESRD patients: Feedback alone versus intensive intervention. J Am Soc Nephrol. 2004;15:754–760
  54. Wolfe RA, Hulbert-Shearon TE, Ashby VB, Mahadevan S, Port FK. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis. 2005;45:127–135
  55. McClellan WM, Krisher JO. Collecting and using patient and treatment center data to improve care: Adequacy of hemodialysis and end-stage renal disease surveillance. Kidney Int Suppl. 2000;74:S7–S13
  56. McClellan WM, Soucie JM, Krisher J, Caruana R, Haley W, Farmer C. Improving the care of patients treated with hemodialysis: A report from the Health Care Financing Administration's ESRD Core Indicators Project. Am J Kidney Dis. 1998;31:584–592
  57. Matchar DB, Patwardhan MB, Samsa GP, Haley WE. Facilitated process improvement: An approach to the seamless linkage between evidence and practice in CKD. Am J Kidney Dis. 2006;47:528–538
  58. McClellan WM. Improving the quality of care for CKD: Can we do it again?. Am J Kidney Dis. 2006;47:549–552
  59. Cook CB, Penman A, Cobb AB, Miller D, Murphy T, Horn T. Outpatient diabetes management of Medicare beneficiaries in four Mississippi fee-for-service primary care clinics. J Miss State Med Assoc. 1999;40:8–13
  60. Jencks SF, Cuerdon T, Burwen DR, et al. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. JAMA. 2000;284:1670–1676
  61. Wu WY, Chen JJ, Shih A. Effect of quality improvement organization activities on outpatient diabetes care in eastern New York State. Med Care. 2006;44:1142–1147
  62. McBean AM, Jung K, Virnig BA. Improved care and outcomes among elderly Medicare managed care beneficiaries with diabetes. Am J Manag Care. 2005;11:213–222
  63. McClellan WM, Millman L, Presley R, Couzins J, Flanders WD. Improved diabetes care by primary care physicians: Results of a group-randomized evaluation of the Medicare Health Care Quality Improvement Program (HCQIP). J Clin Epidemiol. 2003;56:1210–1217
  64. Institute of Medicine. Medicare's Quality Improvement Organization Program: Maximizing Potential (pathways to quality health care) (ed 1). Washington DC: National Academy; 2006;
  65. Brown WW, Collins A, Chen SC, et al. Identification of persons at high risk for kidney disease via targeted screening: The NKF Kidney Early Evaluation Program. Kidney Int Suppl. 2003;83:S50–S55
  66. Hostetter TH, Lising M. National Kidney Disease Education Program. J Am Soc Nephrol. 2003;14(suppl 2):S114–S116
  67. National Institutes of Health. National Kidney Disease Education Program. http://nkdep.nih.gov/Accessed December 21, 2008
  68. Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: A report from the laboratory working group of the National Kidney Disease Education Program. Clin Chem. 2006;52:5–18
  69. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254
  70. Stevens LA, Coresh J, Deysher AE, et al. Evaluation of the MDRD Study equation in a large diverse population. J Am Soc Nephrol. 2007;18:2749–2757
  71. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: The BENEDICT Study. J Am Soc Nephrol. 2006;17(suppl 2):S90–S97
  72. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  73. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–986
  74. Kazmi W, Kausz A, Khan S, et al. Anemia: An early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803–812
  75. Obrador GT, Ruthazer R, Arora P, Kausz A, Pereira BJG. Prevalence of and factors associated with sub-optimal care prior to initiation of dialysis in the United States. J Am Soc Nephrol. 1999;10:1793–1800
  76. Nissenson A, Collins A, Hurley J, Petersen H, Pereira B, Steinberg E. Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns. J Am Soc Nephrol. 2001;12:1713–1720
  77. Kausz AT, Khan SS, Abichandani R, et al. Management of patients with chronic renal insufficiency in the Northeastern United States. J Am Soc Nephrol. 2001;12:1501–1507
  78. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809–2816
  79. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115:114–126
  80. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660–667
  81. Kiberd BA, Jindal KK. Screening to prevent renal failure in insulin dependent diabetic patients: An economic evaluation. BMJ. 1995;311:1595–1599
  82. Palmer AJ, Weiss C, Sendi PP, et al. The cost-effectiveness of different management strategies for type I diabetes: A Swiss perspective. Diabetologia. 2000;43:13–26
  83. Boulware L, Jaar B, Tarver-Carr M, Bruncati F, Powe N. Screening for proteinuria in US adults: A cost-effectiveness analysis. JAMA. 2003;290:3101–3114
  84. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol. 2004;15:1912–1919
  85. Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007;167:1130–1136
  86. Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: An idea whose time has come. Am J Kidney Dis. 2006;47:375–377
  87. Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. Chronic kidney disease: Common, harmful, and treatable—World Kidney Day 2007. Am J Kidney Dis. 2007;49:175–179
  88. McCullough PA, Lepor NE. Piecing together the evidence on anemia: The link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med. 2005;6(suppl 3):S4–S12
  89. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169
  90. Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296:1377–1384
  91. Tonelli M, Moye L, Sacks FM, Kiberd B, Curhan G. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138:98–104
  92. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med. 2006;134:629–636
  93. Solomon SD, Rice MM, Jablonski KA, et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26–31
  94. Queiroz Madeira EP, da Rosa Santos O, Ferreira Santos SF, Alonso da Silva L, MacIntyre Innocenzi A, Santoro-Lopes G. Familial aggregation of end-stage kidney disease in Brazil. Nephron. 2002;91:666–670
  95. Ramirez SP, McClellan W, Port FK, Hsu SI. Risk factors for proteinuria in a large, multiracial, southeast Asian population. J Am Soc Nephrol. 2002;13:1907–1917
  96. McClellan W, Speckman R, McClure L, et al. Prevalence and characteristics of a family history of end-stage renal disease among adults in the United States population: Reasons for Geographic and Racial Differences in Stroke (REGARDS) renal cohort study. J Am Soc Nephrol. 2007;18:1344–1352
  97. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512–519
  98. US National Institutes of Health. National Institute on Aging (Health ABC Description). http://www.nia.nih.gov/ResearchInformation/ScientificResources/HealthABCDescription.htmAccessed February 16, 2008
  99. Notice to Readers: World Kidney Day—March 13, 2008. MMWR Morbid Mortal Wkly Rep. 2008;57:207
  100. Levey AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem: Approaches and initiatives—A position statement from Kidney Disease: Improving Global Outcomes. Kidney Int. 2007;72:247–259

 Because an author of this manuscript is an editor for AJKD, the peer-review and decision-making processes were handled entirely by an Associate Editor (Michael Shlipak, MD, University of California, San Francisco) who served as Acting Editor-in-Chief. Details of the journal's procedures for potential editor conflicts are given in the Editorial Policies section of the AJKD website.

PII: S0272-6386(08)01730-7

doi: 10.1053/j.ajkd.2008.11.019

American Journal of Kidney Diseases
Volume 53, Issue 3 , Pages 522-535 , March 2009

Article Tools

* Image Usage & Resolution